PEPG

SEC source: 0001835597-25-000015 · form4.xml · derivative · entry 3

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,815 shares

Expires 2031-09-05

F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934.

F3 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (September 17, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date.

SEC source: 0001835597-25-000015 · form4.xml · derivative · entry 2

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,705

Underlying: Common Stock · 352,705 shares

Expires 2031-09-05

F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (September 6, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date.

SEC source: 0001835597-25-000015 · form4.xml · derivative · entry 1

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 352,705 shares

Expires 2031-09-05

F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (September 6, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date.

SEC source: 0001856079-25-000003 · primary_doc.xml · nonDerivative · entry 1

Oxford Science Enterprises plc · CIK 0001856079 · Former 10% Owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,955,388

SEC source: 0001231919-25-000265 · form4-09302025_080950.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 18,554,273

F1 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001127602-25-016932 · form4.xml · derivative · entry 1

Mayer Howard · CIK 0001699610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001127602-25-016928 · form4.xml · derivative · entry 1

Dable Habib J · CIK 0001690773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001127602-25-016927 · form4.xml · derivative · entry 1

Resnick Joshua · CIK 0001690959 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: his option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."

SEC source: 0001127602-25-016930 · form4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001127602-25-016931 · form4.xml · derivative · entry 1

HENSON HEIDI · CIK 0001283301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001415889-25-015881 · form4-06062025_120629.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the Issuer's next Annual Stockholder Meeting, provided, however, that all vesting shall cease if Dr. Resnick ceases to serve as a director, unless the Issuer's Board of Directors determines that the circumstances warrant continuation of vesting.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001127602-25-016227 · form4.xml · nonDerivative · entry 1

STRECK PAUL · CIK 0001708063 · EVP, Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,805

F1 · price: Shares of Common Stock purchased pursuant to the PepGen Inc. 2022 Employee Stock Purchase Plan ("ESPP"), for the purchase period of December 1, 2024 to May 30, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of PepGen's Common Stock on May 30, 2025.

SEC source: 0001127602-25-015213 · form4.xml · derivative · entry 2

Kasraian Kasra · CIK 0002068538 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-05-19

F2 · derivative.exercise_date: The option shall vest as follows: twenty-five (25%) of the shares subject to the Option will vest and become exercisable on the first anniversary of the Vesting Commencement Date and, thereafter, the remaining seventy-five percent (75%) of the shares subject to the Option shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the first anniversary of the Vesting Commencement Date, in each case, subject to the Officer's continuous service with the Company through each vesting date.

SEC source: 0001127602-25-015213 · form4.xml · nonDerivative · entry 1

Kasraian Kasra · CIK 0002068538 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,750

F1 · date: Twenty-five percent (25%) of the shares subject to the RSU will vest on the first anniversary of the Vesting Commencement Date and, thereafter, the remaining seventy-five (75%) will vest in substantially equal installments, in each case subject to the Officer's continuous service with the Company through each vesting date.

SEC source: 0001127602-25-012400 · form4.xml · nonDerivative · entry 1

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,913

F1 · price: Shares of Common Stock purchased on the open market on April 17, 2025 at prices ranging from $1.335 to $1.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001127602-25-011837 · form4.xml · nonDerivative · entry 1

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,913

F1 · price: Shares of Common Stock purchased on the open market on April 8, 2025 at prices ranging from $1.145 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001127602-25-010661 · form4.xml · derivative · entry 1

Wyman Lisa · CIK 0002062689 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2035-03-26

F1 · derivative.exercise_date: The option shall vest as follows: 1/3 on the first anniversary of such Outside Director's election to the Board of Directors, and the remainder ratably in equal monthly installments over the remaining two years, provided, however, that all vesting shall cease if the individual ceases to serve as a director of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting

SEC source: 0001127602-25-010663 · form4.xml · derivative · entry 1

Finer Mitchell H. · CIK 0001578432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2035-03-26

F1 · derivative.exercise_date: The option shall vest as follows: 1/3 on the first anniversary of such Outside Director's election to the Board of Directors, and the remainder ratably in equal monthly installments over the remaining two years, provided, however, that all vesting shall cease if the individual ceases to serve as a director of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001127602-25-008366 · form4.xml · derivative · entry 2

Donnelly Noel · CIK 0001922546 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,250

Underlying: Common Stock · 104,250 shares

Expires 2035-03-02

F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-25-008366 · form4.xml · nonDerivative · entry 1

Donnelly Noel · CIK 0001922546 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,956

F1 · shares: Consists of shares of Common Stock issuable under 23,283 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 3, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

F2 · balance_after: Includes of 23,283 shares of unvested RSUs.

SEC source: 0001127602-25-008369 · form4.xml · derivative · entry 2

DeLena Mary Beth · CIK 0001553878 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-03-02

F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-25-008369 · form4.xml · nonDerivative · entry 1

DeLena Mary Beth · CIK 0001553878 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,968

F1 · shares: .Consists of shares of Common Stock issuable under 13,400 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 3, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

F2 · balance_after: Includes of 13,400 shares of unvested RSUs.

SEC source: 0001127602-25-008365 · form4.xml · derivative · entry 2

STRECK PAUL · CIK 0001708063 · EVP, Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2035-03-02

F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-25-008365 · form4.xml · nonDerivative · entry 1

STRECK PAUL · CIK 0001708063 · EVP, Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,430

F1 · shares: .Consists of shares of Common Stock issuable under 19,430 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 3, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-25-008359 · form4.xml · derivative · entry 2

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,875

Underlying: Common Stock · 271,875 shares

Expires 2035-03-02

F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-25-008359 · form4.xml · nonDerivative · entry 1

McArthur James G · CIK 0001763307 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,413

F1 · shares: Consists of shares of Common Stock issuable under 60,719 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 3, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date.

F2 · balance_after: Includes of 60,719 shares of unvested RSUs.

SEC source: 0001127602-25-006999 · form4.xml · nonDerivative · entry 2

Donnelly Noel · CIK 0001922546 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,673

F2 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of the PSUs reported in this form. The mandatory sale of the Reporting Person's shares was provided for in a PSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001127602-25-007006 · form4.xml · nonDerivative · entry 2

DeLena Mary Beth · CIK 0001553878 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,568

F2 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units awarded to the Reporting Person on February 24, 2025. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001127602-25-006999 · form4.xml · nonDerivative · entry 1

Donnelly Noel · CIK 0001922546 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

F1 · shares: On February 6, 2024, the Reporting Person was granted performance-based stock units ("PSUs") under the 2022 Stock Option and Incentive Plan. Each PSU represents the right to receive one share of Common Stock upon vesting. The shares reported were issued to the Reporting Person upon achievement of a performance condition on February 24, 2025, as determined by the Compensation Committee of the Company's Board of Directors.

SEC source: 0001127602-25-007006 · form4.xml · nonDerivative · entry 1

DeLena Mary Beth · CIK 0001553878 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

F1 · shares: On February 6, 2024, the Reporting Person was granted performance-based stock units ("PSUs") under the 2022 Stock Option and Incentive Plan. Each PSU represents the right to receive one share of Common Stock upon vesting. The shares reported were issued to the Reporting Person upon achievement of a performance condition on February 24, 2025, as determined by the Compensation Committee of the Company's Board of Directors.

SEC source: 0001127602-24-022610 · form4.xml · derivative · entry 2

STRECK PAUL · CIK 0001708063 · EVP, Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,816

Underlying: Common Stock · 40,000 shares

Expires 2034-08-18

F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-022610 · form4.xml · derivative · entry 1

STRECK PAUL · CIK 0001708063 · EVP, Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,816

Underlying: Common Stock · 202,816 shares

Expires 2034-08-18

F1 · shares: The option has been granted pursuant to the PepGen Inc. 2024 Inducement Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-021044 · form4.xml · derivative · entry 6

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 7,571 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F4 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-021044 · form4.xml · nonDerivative · entry 4

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-24-021044 · form4.xml · nonDerivative · entry 3

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,571

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-021044 · form4.xml · derivative · entry 5

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,571

Underlying: Common Stock · 201 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F4 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-021044 · form4.xml · nonDerivative · entry 2

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-24-021044 · form4.xml · nonDerivative · entry 1

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-020735 · form4.xml · derivative · entry 3

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,772

Underlying: Common Stock · 12,625 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-020735 · form4.xml · nonDerivative · entry 2

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-24-020735 · form4.xml · nonDerivative · entry 1

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-020521 · form4.xml · derivative · entry 6

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,397

Underlying: Common Stock · 5,901 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F4 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-020521 · form4.xml · nonDerivative · entry 4

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-24-020521 · form4.xml · nonDerivative · entry 3

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,901

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-020521 · form4.xml · derivative · entry 5

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,298

Underlying: Common Stock · 3,288 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F4 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-020521 · form4.xml · nonDerivative · entry 2

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-24-020521 · form4.xml · nonDerivative · entry 1

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,288

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-019998 · form4.xml · derivative · entry 6

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,586

Underlying: Common Stock · 37 shares

Expires 2032-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-24-019998 · form4.xml · nonDerivative · entry 4

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.

SEC source: 0001127602-24-019998 · form4.xml · nonDerivative · entry 3

Mellion Michelle L · CIK 0001923040 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.